Press release
Endometriosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Endometriosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Endometriosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Endometriosis Pipeline Report
* In January 2025:- Organon and Co .- The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
* In January 2025:- AbbVie - A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain.
* DelveInsight's Endometriosis pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Endometriosis treatment.
* The leading Endometriosis Companies such as ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
* Promising Endometriosis Therapies such as Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.
Discover how the endometriosis treatment paradigm is evolving. Access DelveInsight's in-depth Endometriosis Pipeline Analysis for a closer look at promising breakthroughs @ Endometriosis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Endometriosis Emerging Drugs Profile
* Linzagolix: ObsEva
ObsEva is currently advancing linzagolix, a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries. Through previously reported results from linzagolix and sophisticated pharmacological modelling, it has been established that maintaining estradiol within a specific target range provides the optimal balance between reducing symptoms while mitigating bone density loss associated with excessive estradiol suppression.
* HMI-115: Hope Medicine (Nanjing) Co., Ltd
HMI-115 is a first-in-class monoclonal antibody drug that Hope Medicine owns the global rights. In April 2019, Hope Medicine and Bayer AG signed an exclusive global license agreement for the development and commercialization of HMI-115, a monoclonal antibody targeting the prolactin receptor (PRLR), for multiple indications globally. Potential indications for the antibody include Endometriosis (EM), Androgenic Alopecia (AGA), and other chronic diseases. In 2021, Hope Medicine received approval from the FDA and EMA to conduct MRCT Phase II clinical trials for the treatment of endometriosis Hope Medicine has now completed patient enrollment and dosing at all clinical trial centers in the US and Europe.
* VAL-301: ValiRx
VAL-301 is a small molecule, peptide, and new chemical entity it is developed in-house by ValiRx, under evaluation by an undisclosed Japanese Pharmaceutical Company. VAL301 peptide re-purposed towards non-cancerous cell proliferation. The mechanism of action of drug candidate is inhibition of androgen activation of SRC kinase. Currently, the drug is in preclinical stage of its development for the treatment of endometriosis.
Get a detailed analysis of the latest innovations in the endometriosis pipeline. Explore DelveInsight's expert-driven report today! @ Endometriosis Unmet Needs [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Endometriosis Companies
ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Endometriosis Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Endometriosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Endometriosis Pipeline Report
* Coverage- Global
* Endometriosis Companies- ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
* Endometriosis Therapies- Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.
* Endometriosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Endometriosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in endometriosis drug development? Find out in DelveInsight's exclusive Endometriosis Pipeline Report-access it now! @ Endometriosis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Endometriosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Endometriosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Linzagolix: ObsEva
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HMI-115: Hope Medicine (Nanjing) Co., Ltd
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* VAL-301: ValiRx
* Drug profiles in the detailed report.....
* Inactive Products
* Endometriosis Key Companies
* Endometriosis Key Products
* Endometriosis- Unmet Needs
* Endometriosis- Market Drivers and Barriers
* Endometriosis- Future Perspectives and Conclusion
* Endometriosis Analyst Views
* Endometriosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endometriosis-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3855000 • Views: …
More Releases from ABNewswire
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Endometriosis
Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction
Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern.
Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays…
Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market: A Ke …
The Endometriosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Endometriosis Market Size and Its Estimated Growth Rate?
In recent years, there has been a swift expansion in the market size of endometriosis. This market is projected to increase from $1.4 billion…
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare
EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to…
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size?
The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups.
The…
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Endometriosis Market Size, Share, Insight, Treatment 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Endometriosis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.01 billion In 2028 At A…
